View Older Stories View More Recent Stories

May 22, 2018 09:00AM Horizon Pharma plc Launches GoutRevealed.com to Spotlight the Journey and Stories of People Living with Uncontrolled Gout
May 9, 2018 07:00AM Horizon Pharma plc Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth; Increases Full-Year 2018 Guidance and Announces New Company Operating Structure to Enhance Focus on Rare
May 9, 2018 07:00AM Horizon Pharma plc Reports Strong First-Quarter 2018 Orphan and Rheumatology Net Sales Growth; Increases Full-Year 2018 Guidance and Announces New Company Operating Structure to Enhance Focus on Rare
May 8, 2018 08:11AM National Health Partners (HPR) Announces USPTO Issuance of Additional Notices of Allowance With Claims Covering RAVICTI Oral Liquid
May 8, 2018 08:00AM Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notices of Allowance With Claims Covering RAVICTI® (glycerol phenylbutyrate) Oral Liquid
May 4, 2018 08:00AM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 3, 2018 08:00AM Horizon Pharma plc Announces Sangita Iyer as a 2018 Healthcare Businesswomen’s Association Rising Star
May 1, 2018 08:00AM Horizon Pharma plc to Participate in the UBS Global Healthcare Conference
Apr 12, 2018 04:30PM Horizon Pharma plc Named No. 1 Biopharma Company to Work for by Great Place to Work® and FORTUNE
Apr 9, 2018 08:00AM Horizon Pharma plc to Release First-Quarter 2018 Financial Results and Host Webcast on May 9, 2018
Apr 4, 2018 08:00AM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 6, 2018 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 28, 2018 07:00AM Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2017 Results
Feb 28, 2018 07:00AM Horizon Pharma plc Announces Fourth-Quarter and Full-Year 2017 Results
Feb 28, 2018 05:58AM Horizon Pharma (HZNP) Reports Submission of Supplemental NDA for RAVICTI (glycerol phenylbutyrate) Oral Liquid
Feb 27, 2018 06:00PM Horizon Pharma plc Submits Supplemental New Drug Application for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Expand Age Range to Include Newborns
Feb 26, 2018 08:00AM Horizon Pharma Gift Establishes First Clinical Team Endowment at Children’s National Rare Disease Institute
Feb 26, 2018 07:00AM Horizon Pharma plc to Participate in the Cowen and Company 38th Annual Health Care Conference
Feb 22, 2018 09:00AM Horizon Pharma plc Announces Release of the First RAREis™ Song in Partnership with Sing Me a Story Foundation and Global Genes
Feb 6, 2018 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 30, 2018 08:30AM Horizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis Community
Jan 29, 2018 08:00AM Horizon Pharma plc to Release Fourth-Quarter and Full-Year 2017 Financial Results and Host Webcast on Feb. 28, 2018
Jan 8, 2018 07:25AM UPDATE: Horizon Pharma (HZNP) Reports Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune
Jan 8, 2018 07:24AM Horizon Pharma (HZNP) Increases Peak Net Sales Guidance, Announces Rheumatology and Orphan Pipeline Developments
Jan 8, 2018 07:05AM Horizon Pharma plc Increases Peak Net Sales Guidance for Key Growth Drivers and Announces Rheumatology and Orphan Pipeline Developments
Jan 8, 2018 07:00AM Horizon Pharma plc Announces Agreement to License Pre-Clinical Uricase Derivative (MEDI4945) from MedImmune
Jan 5, 2018 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jan 4, 2018 07:30AM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Dec 27, 2017 08:01AM Horizon Pharma (HZNP) PROCYSBI Approved by FDA for Expanded Indication
Dec 27, 2017 08:00AM Horizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathi
Dec 18, 2017 09:23AM Horizon Pharma plc to Present at the 36th Annual J.P. Morgan Healthcare Conference
Dec 5, 2017 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 30, 2017 04:05PM Horizon Pharma plc to Participate in BMO Prescriptions for Success Healthcare Conference
Nov 30, 2017 06:00AM Horizon Pharma plc Names Shao-Lee Lin, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
Nov 10, 2017 09:30AM Horizon Pharma plc Selected as One of Chicago’s Top Workplaces by the Chicago Tribune
Nov 7, 2017 04:05PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 6, 2017 12:00PM Horizon Pharma plc Presents New Data at 2017 ACR/ARHP Annual Meeting, Advances Clinical Understanding of KRYSTEXXA® (pegloticase injection) in Adults with Uncontrolled Gout
Nov 6, 2017 07:00AM Horizon Pharma plc Announces Third-Quarter and Year-to-Date 2017 Results
Nov 4, 2017 11:00AM Horizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of Age
Nov 3, 2017 11:02AM National Health Partners (HPR) Announces Poster Presentation on KRYSTEXXA at ASN
Nov 3, 2017 11:00AM Horizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017
Nov 2, 2017 04:05PM Horizon Pharma plc to Participate in Investor Conferences in November
Oct 26, 2017 08:08AM Horizon Pharma plc (HZNP) Reports Availability of PROCYSBI (cysteamine bitartrate) in Canada
Oct 26, 2017 08:00AM Horizon Pharma plc Announces Availability of PROCYSBI™ (cysteamine bitartrate) in Canada
Oct 25, 2017 08:15AM Horizon Pharma (HZNP) Reports First Patient Enrolled in Confirmatory Phase 3 Clinical Trial
Oct 25, 2017 08:00AM Horizon Pharma plc Announces First Patient Enrolled in Confirmatory Phase 3 Clinical Trial Evaluating Teprotumumab for the Treatment of Moderate-to-Severe Active Thyroid Eye Disease
Oct 23, 2017 08:00AM Horizon Pharma plc to Present KRYSTEXXA® (pegloticase injection) Data for the Management of Uncontrolled Gout at the 2017 ACR/ARHP Annual Meeting
Oct 17, 2017 08:30AM Horizon Pharma plc Named One of the Best Small & Medium Workplaces by FORTUNE and Great Place to Work® for the Second Year in a Row
Oct 10, 2017 07:00AM Horizon Pharma plc to Host Third-Quarter 2017 Conference Call and Webcast on Nov. 6, 2017
Oct 2, 2017 04:30PM Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
View More Recent Stories View Older Stories